



*A Joint meeting between the Nutrition Society and the Royal Society of Medicine was held at the Royal Society of Medicine, London on 11–12 December 2012*

## Conference on ‘Dietary strategies for the management of cardiovascular risk’

### ‘The way to a man’s heart is through his gut microbiota’ – dietary pro- and prebiotics for the management of cardiovascular risk

Kieran M. Tuohy\*, Francesca Fava and Roberto Viola

*Nutrition and Nutrigenomics Group, Department of Food Quality and Nutrition, Research and Innovation Centre, Fondazione Edmund Mach, San Michele all’Adige, Trento 38010, Italy*

The human gut microbiota has been identified as a possible novel CVD risk factor. This review aims to summarise recent insights connecting human gut microbiome activities with CVD and how such activities may be modulated by diet. Aberrant gut microbiota profiles have been associated with obesity, type 1 and type 2 diabetes and non-alcoholic fatty liver disease. Transfer of microbiota from obese animals induces metabolic disease and obesity in germ-free animals. Conversely, transfer of pathogen-free microbiota from lean healthy human donors to patients with metabolic disease can increase insulin sensitivity. Not only are aberrant microbiota profiles associated with metabolic disease, but the flux of metabolites derived from gut microbial metabolism of choline, phosphatidylcholine and L-carnitine has been shown to contribute directly to CVD pathology, providing one explanation for increased disease risk of eating too much red meat. Diet, especially high intake of fermentable fibres and plant polyphenols, appears to regulate microbial activities within the gut, supporting regulatory guidelines encouraging increased consumption of whole-plant foods (fruit, vegetables and whole-grain cereals), and providing the scientific rationale for the design of efficacious prebiotics. Similarly, recent human studies with carefully selected probiotic strains show that ingestion of viable microorganisms with the ability to hydrolyse bile salts can lower blood cholesterol, a recognised risk factor in CVD. Taken together such observations raise the intriguing possibility that gut microbiome modulation by whole-plant foods, probiotics and prebiotics may be at the base of healthy eating pyramids advised by regulatory agencies across the globe. In conclusion, dietary strategies which modulate the gut microbiota or their metabolic activities are emerging as efficacious tools for reducing CVD risk and indicate that indeed, the way to a healthy heart may be through a healthy gut microbiota.

#### **Gut microbiota: CVD: Probiotic: Prebiotic: Metabolites**

CVD is mediated by different risk factors both modifiable and non-modifiable. Age, sex and genetics, or particular genotypes (e.g. apoE4), represent non-modifiable risk factors which impact directly on an individual’s likelihood of developing CVD. CVD risk is also shaped by a number of modifiable largely environmental risk factors often linked to diet and lifestyle, e.g. smoking, chronic low-grade systemic inflammation (sometimes called metabolic endotoxemia), dyslipidaemia, high blood pressure, diabetes and insulin resistance, metabolic syndrome, overweight/obesity<sup>(1,2)</sup>. Recent studies in

animal models and in human subjects have identified another extra-genomic contributor to CVD risk, the gut microbiota. Aberrant gut microbiota profiles have been associated with obesity, type 1 and type 2 diabetes, non-alcoholic fatty liver disease, certain cancers and various autoimmune diseases<sup>(3–10)</sup>. Recent experimental studies have shown that transfer of faecal microbiota can induce metabolic disease and obesity, indicating that the gut microbiota possess an intricate relationship with mammalian physiological processes linked to CVD risk. In a paradigm-shifting experiment, Bäckhed

**Abbreviations:** BA, bile acid; LPS, lipopolysaccharide; SRB, sulphate-reducing bacteria; TMA, trimethylamine; TMAO, trimethylamine-N-oxide.  
**\*Corresponding author:** K. M. Tuohy, fax 0039 0461 615200, email kieran.tuohy@fmach.it

*et al.*<sup>(11)</sup> showed that the obese phenotype, and associated insulin resistance and inflammatory profiles could be transferred along with faecal microbiota from obese animals to lean germ-free counterparts. More recently, Vrieze *et al.*<sup>(12)</sup> showed that faecal transfer from lean healthy human donors to male metabolic syndrome subjects could increase insulin sensitivity 6 weeks after the transfer and also increase the levels of butyrate-producing intestinal bacteria. Such intriguing experiments illustrate clearly that the gut microbiota may at once contribute to CVD risk and also represent a realistic therapeutic target<sup>(13–15)</sup>.

Diet appears to critically influence both the relative abundance of different gut microorganisms and their metabolic output. Animal and a limited number of human studies have shown that diets high in fat or animal protein can radically remodel the gut microbiota, reducing the relative abundance of bifidobacteria and butyrate-producing bacteria, considered beneficial to health, and increasing the concentration of harmful microbially derived metabolites<sup>(13–18)</sup>. On the contrary, other studies have shown that supplementing high-fat diets with fermentable fibres or prebiotics can increase the relative abundance of bifidobacteria and butyrate-producing bacteria and SCFA production, all seen as beneficial activities<sup>(19–23)</sup>. These fermentable fibres and prebiotics, including inulin, oligofructose,  $\beta$ -glucan, resistant starch and pectin, have long been studied in animal models for their ability to reduce insulin resistance, plasma cholesterol levels and atherosclerotic plaques<sup>(23–26)</sup>. This work is also supported by epidemiological data demonstrating an inverse association between the consumption of dietary fibre and CVD risk<sup>(27,28)</sup>. Moreover, recent human dietary interventions have shown that with careful choice of probiotic strain, it is possible to reduce blood cholesterol, an indirect marker of CVD risk, by augmenting microbial involvement in the enterohepatic circulation of bile acids (BA) and reducing fat absorption from the intestine<sup>(29,30)</sup>.

### **An anthropology of diet: microbe interactions within the human gut**

The human intestinal tract is colonised by a microbiota of some 1000 different microbial species. Each microorganism within the gut encodes unique metabolic functions which taken together comprise the gut microbiome. Indeed, the metabolic potential of the gut metagenome, or the sum of microbial encoded genes is about 100-fold that of the human genome, and even with functional redundancy between different microbial species, represents a metabolic potential rivaling that of the liver both in chemical diversity and impact on host health<sup>(31–33)</sup>. The close association between host physiology and this diverse intestinal microbiota is clearly demonstrated by the critical gut microbiota contribution to the establishment and maintenance of a tolerogenic and well functioning immune system, a process greatly impacted by both diet and microbial passengers in the diet<sup>(34–37)</sup>. However, signals between the gut microbiota

and human immune system too can get lost in translation leading to the activation of pathological processes. Certain microbial proteins for example share the considerable structural homology to human proteins including leptin and gut satiety hormones involved in controlling food intake and to which autoantibodies are raised in metabolic disease<sup>(38–42)</sup>. Such observations raise the intriguing possibility that aberrant gut microbiota profiles may be more than coincidental consequences of poor diet, but may actually play a pathological role in these chronic diet-associated diseases.

The human genome has evolved closely with its microbial counterpart over the course of evolution, resulting in many shared or co-metabolic pathways. Through these shared metabolic pathways the mammalian host derives energy and nutrients from its diet which otherwise would be lost in faeces. For example, many complex plant polysaccharides require the activities of both human encoded enzymes and microbial enzymes in the colon to release sugar monomers and SCFA later upon fermentation<sup>(43)</sup>. Similarly, up to 95% of plant polyphenols escape digestion in the upper gut and reach the colon where they are transformed by the resident microbiota into biological available and often biologically active intermediates<sup>(26,44,45)</sup>. In addition, the gut microbiota also plays a critical role in the enterohepatic circulation of BA, a process closely linked to circulating cholesterol levels.

For the vast majority of evolutionary time, human subjects existed as hunter gatherers, collecting diverse wild species of fruit, vegetables, seeds and root tubers rich in starch, inulin and other complex polysaccharides, and hunting wild game<sup>(31)</sup>. This ancient diet, close to extant traditional diets based on high intake of whole-plant foods, e.g. the Mediterranean diet, is radically different from the current prevailing Western-style diet characterised by foods rich in fat, animal protein, flavouring agents, particularly sugars, salt and monosodium glutamate, and low in fibre, plant phytochemicals, beneficial fats, minerals and vitamins. Considering the ability of plant polyphenols to inhibit certain gut bacteria and stimulate the growth of others<sup>(46,47)</sup>, the ability of these same antioxidant polyphenols to alter redox potential within the gastrointestinal tract thereby reducing the absorption of oxidised cholesterol species<sup>(48)</sup>, and the key role of fermentable fibres/prebiotics in shaping the composition and metabolic activity of the gut microbiota<sup>(22,31,49)</sup>, it is no wonder that the chronic diet-associated diseases, both metabolic and autoimmune in nature which are reaching epidemic proportions in the developed world are virtually unheard of in populations following these more traditional diets in diverse regions of the world<sup>(50–54)</sup>. In a study using 16S rRNA-based metagenomics to characterise the composition and metabolic output of the faecal microbiota from children growing up in urban Florence, Italy and rural Burkina Faso in Africa it was found that the profile of bacteria was strikingly different between healthy, age-matched children growing up in the two very different settings<sup>(55)</sup>. In the African children, following a typical traditional rural African diet consisting principally of whole-plant

foods, cereals and fermented fruits, supplemented very occasionally with bush meat and insect protein, a gut microbiota dominated by Bacteroidetes phylum and especially the *Prevotella* group, indicative of high capacity for carbohydrate fermentation was observed. Conversely, the gut microbiota of the Italian children following a fairly typical Western-style diet, was dominated by Firmicutes and enriched with  $\gamma$ -Proteobacteria. This modulation of Bacteroidetes: Firmicutes ratio was described earlier in obese human subjects and animal models of obesity, with the obese having higher proportions of Firmicutes. The Gram-negative  $\gamma$ -Proteobacteria enriched in the Italian children included *Escherichia coli*, *Salmonella*, *Shigella* and *Klebsiella*, bacteria which include some of the most common human gastrointestinal pathogens. In addition, the African children appeared to have enhanced production of SCFA, with about 3-fold the concentration of acetate, butyrate and propionate in their faeces compared with the Italian children. Although SCFA concentrations in faeces are poor indicators of SCFA production in the gut, their potential to modulate disease mechanisms linked to CVD are well reported<sup>(15,56–59)</sup>. Similar results were observed by Yatsunenکو *et al.*<sup>(60)</sup> who studied the effect of age and geography on the faecal microbiota of populations in the USA, Amazonia and Malawi. These authors confirmed the dominance of bifidobacteria within the infant gut microbiota irrespective of geography, the trade-off between Bacteroides and *Prevotella* within the phylum Bacteroidetes in Westerners compared with traditional populations, and that the Westernised-type microbiota was enriched for simple sugar and protein metabolism in both infants and adults.


Consumption of whole-plant foods, fruit, vegetables and whole-grain cereals has long been at the core of healthy eating guidelines. Current recommendations in the USA encourage consumers to 'increase vegetable and fruit intake', and to 'consume at least half of all grains as whole grains. Increase whole-grain intake by replacing refined grains with whole grains'<sup>(61)</sup>. In the UK, the Food Standards Agency 'Eatwell Plate' states that 'starchy foods such as bread, cereals, rice, pasta and potatoes are a really important part of a healthy diet. Try to choose whole-grain varieties whenever you can', and to eat 'plenty of fruit and vegetables'<sup>(62)</sup>. Much of the evidence for these dietary guidelines comes from large-scale epidemiological studies and recent meta-analyses of intervention studies showing that both food groups, fruit and vegetables and whole-grain cereals, are inversely associated with CVD risk<sup>(63–98)</sup>. However, many of these foods, and their functional molecular components, especially fermentable fibres and polyphenolic compounds have recently been shown to modulate the human gut microbiota towards a more health-promoting profile. Fermentable fibres, especially the prebiotics, increase the relative abundance of bifidobacteria, lactobacilli and butyrate-producing bacteria, all considered beneficial bacteria. Many have anti-inflammatory properties, some have been shown to improve gut wall barrier function and many also possess bile salt hydrolase activity with the ability to impact on

BA signalling both within the gut and systemically. Fermentation of these compounds also leads to the production of SCFA, which as discussed later, impact on important physiological processes linked to CVD. The 95% of dietary polyphenols, which reach the colon and become available for microbial transformation represent a chemically diverse class of food molecules with potential to impact on CVD. While many studies have focused on the ability of the specific plant polyphenols to reduce CVD risk by impacting inflammation, oxidative stress, cholesterol/BA binding, platelet function, vasodilation, foam cell formation, cholesterol and glucose homeostasis and thermogenesis, a few have examined the impact of the microbial catabolites of these plant polyphenols. This is an important distinction, as most plant polyphenols are not absorbed and it is their microbial catabolites which have potential to act systemically<sup>(26,70)</sup>. Interestingly, certain whole fruits and polyphenol-rich fruit extracts have also been recently shown to increase the relative abundance of bifidobacteria, lactobacilli and butyrate-producing bacteria within the human gut microbiota<sup>(46,47,71)</sup>. However, a detailed description of these polyphenol-related activities is beyond the scope of this present review but has been discussed elsewhere<sup>(44,70)</sup>. It is worth noting though, that polyphenols and fermentable fibres as they occur in whole-plant foods may act in tandem or even synergistically often through the gut microbiota to improve different physiological processes linked to CVD risk and that the biological activity of whole-plant foods appears to be greater than the sum of their biologically active components.

*Diet can bring out the best of microbial behaviours:  
microbiome symbiosis*

Microorganisms within the human intestine ferment carbohydrate sources, which reach the colon into the SCFA acetate, propionate and butyrate<sup>(15)</sup>. These small organic acids have been shown in animal studies to regulate incretin or gut hormone production, thereby controlling satiety and food intake<sup>(15,72,74)</sup>. They also stimulate the gut hormone glucagon-like peptide-2, which is involved in maintaining gut barrier function, a defense mechanism, which can impede the uptake of inflammatory compounds such as lipopolysaccharide (LPS) from the gut lumen that trigger the low-grade chronic inflammation and subsequent insulin resistance associated with obesity and CVD<sup>(73,74)</sup>. Similarly, SCFA have been shown to regulate adipocyte hormone production, not least of leptin<sup>(75)</sup>, the obesity hormone, and to control inflammatory processes in adipose tissue<sup>(76)</sup>, processes intimately involved in CVD risk, and possibly also impact on the way energy is stored or burnt in the body controlling adiposity and thermogenesis<sup>(15,77)</sup>.

Microbial deconjugation of BA and the enterohepatic circulation of BA is a core activity of the human gut microbiota and is thought to directly regulate cholesterol levels in the blood<sup>(78,79)</sup>. Conjugated BA are secreted into the small intestine to aid micelle formation and fat absorption. About 5% of BA may pass to the distal ileum and colon where they undergo deconjugation by



**Fig. 1.** (colour online) A schematic representation of how diet shapes the human gut microbiota and impacts on chronic disease risk.

the gut microbiota reducing their absorbability and increasing their loss in faeces. Since BA synthesis from cholesterol is under tight control in the liver, BA lost in faeces must be replaced driving hepatic uptake and metabolism of circulating cholesterol<sup>(80,81)</sup>. Indeed, increased loss of BA or cholesterol in faeces has long been suggested as a mode of action of dietary fibres and whole-plant foods in lowering blood cholesterol<sup>(82–84)</sup>. However, more recent studies are suggesting that this may not be the whole picture. Intriguingly, deconjugated BA may also be absorbed<sup>(30)</sup>. BA and deconjugated BA are emerging as important cell-signalling molecules, interacting with nuclear receptors such as Farnesoid X receptor (FXR), Pregnane X receptor (PXR) and Peroxisome proliferator-activated receptor alpha (PPAR $\alpha$ ) and G-protein-coupled receptors such as TGR-5, which regulate inflammation, xenobiotic detoxification, lipid metabolism, cholesterol biosynthesis and uptake, BA metabolism, glucose homeostasis and thermogenesis<sup>(81,85–88)</sup>. However, the specific mechanistic studies in animals and human dietary interventions including analysis of the gut microbiota and their metabolic activities with foods capable of modulating the enterohepatic circulation of BA (e.g. probiotics, prebiotics, polyphenols and whole-plant foods) are needed to confirm which gut bacteria are involved in BA metabolism and how their modulation through dietary means alters BA profiles entering the enterohepatic circulation and any subsequent impact on CVD risk.

Other metabolites derived from microbial metabolism in the gut have also been shown to reduce the risk of metabolic disease, at least in animal studies. The neurotransmitter  $\gamma$ -aminobutyric acid is also produced by gut bacteria including certain lactic acid bacteria<sup>(89)</sup>. Gamma-Aminobutyric acid given orally is also a strong regulator of inflammation and immune function, and has been shown to reduce the risk of metabolic disease by improving insulin sensitivity through reduced inflammation in laboratory animals on a high-fat, obesogenic diet<sup>(90)</sup>. Certain gut bacteria, most notably the bifidobacteria,

have been shown to produce folate, a key metabolite C<sub>1</sub> metabolism which lowers circulating levels of homocysteine, an independent risk factor of CVD<sup>(91)</sup>. Animal studies have shown that feeding folate-producing bifidobacteria can increase plasma folate concentrations, and that co-administration of the *Bifidobacterium* strain with a substrate for its growth within the intestine, the prebiotic inulin, can increase plasma folate concentrations further in a synergistic manner<sup>(92)</sup>. Gut bacteria may also interact with dietary fats. We have shown that both the quantity and type of dietary fat can reshape the microbial community structure within the gut<sup>(16,18)</sup>. Conversely, it has been shown in a study at Teagasc in Ireland that bifidobacteria capable of biohydrogenation of fatty acids, when administered to pigs or mice along with  $\alpha$ -linoleic acid can increase concentrations of beneficial fats, EPA, DHA and conjugated linoleic acid concentrations in extra-intestinal organs including adipose tissue, liver and brain<sup>(93,94)</sup>, indicating that at least certain bifidobacterial strains can alter dietary fats *in vivo*, and increase body stores of beneficial fats. Conjugated linoleic acid, EPA and DHA have long been studied for anti-inflammatory properties and association with reduced risk of CVD and other metabolic diseases<sup>(95,96)</sup> (Fig. 1).

*Diet can bring out the worst of microbial behaviours: microbiome dysbiosis*

Choline-deficient diets have long been used to induce insulin resistance and metabolic disease in animal models and the gut microbiota is recognised to play an important role in the co-metabolic processing of choline and phosphatidylcholine in man<sup>(97,98)</sup>. Dumas *et al.*<sup>(99)</sup> investigated the impact of choline metabolism disruption on the development of metabolic disease and non-alcoholic fatty liver disease in mice prone to disease (129S6) and in mice resistant to disease (BALBc) using NMR-based metabolomics. These investigators found that low plasma levels of phosphatidylcholine and increased urinary excretion of methylamines (dimethylamine, trimethylamine (TMA) and trimethylamine-N-oxide, (TMAO)) was associated with insulin resistance and fatty liver phenotype. Importantly these metabolites result from host:microbiota co-metabolic processing of choline and phosphatidylcholine<sup>(97)</sup>. Dumas *et al.*<sup>(99)</sup> demonstrated that microbial conversion of choline into methylamines is induced by high-fat feeding and mimics the disease effects of choline-deficient diets. Other studies have shown that high-fat, low fermentable fibre diets, typically used to induce metabolic disease in laboratory animals decimate the gut microbiota. Cani *et al.*<sup>(16)</sup> showed that high-fat, low fermentable fibre feeding leads to significant die off in dominant and putatively beneficial gut bacteria including bifidobacteria, butyrate-producing Firmicutes and polysaccharide degrading Bacteroidetes. Interestingly, high-fat feeding did not change numbers of Gram-negative sulphate-reducing bacteria (SRB) in these experiments. Decimation of beneficial gut bacteria was accompanied by translocation of bacterial cell wall LPS across the gut wall, either through increased permeability due to

reduced tight junction control or carried with fat absorbed from the gut. LPS is an inflammatory cell wall constituent of Gram-negative bacteria and triggers inflammatory cascade through Toll-like receptor-4 or CD14, and NF- $\kappa$ B, and in the high-fat-fed animals, plasma LPS triggers low-grade chronic inflammation and subsequent insulin resistance and body weight gain<sup>(16)</sup>. Interestingly, Zhang *et al.*<sup>(17)</sup> more recently showed that in another murine model of metabolic disease (*ApoA-I* knockout mice on high-fat diet), the SRB, *Desulfovibrionaceae*, showed higher relative abundance in animals with insulin resistance, especially insulin-resistant animals fed high-fat diets. In this study too, numbers of bifidobacteria were decimated by high-fat feeding. SRB, which convert mainly dietary sulphate to H<sub>2</sub>S, are considered to play an important role in human H<sub>2</sub>S metabolism<sup>(100,101)</sup>, have been implicated in inflammatory bowel disease and their LPS is highly inflammatory. More recently, in common with certain other gut bacteria, SRB have also been shown to be capable of converting choline to TMA under anaerobic conditions, using a glycyl radical enzyme<sup>(102)</sup>. TMA in human subjects is further converted into TMAO by the hepatic enzyme flavin-dependent monooxygenase 3. Interestingly, TMA, the microbial precursor of TMAO, also acts as a substrate for methanogenesis, being metabolised to innocuous CH<sub>4</sub>, raising the intriguing possibility that modulation of the relative abundance of methanogens:SRB within the human gut might regulate the production of cardiotoxic TMAO or innocuous CH<sub>4</sub> gas. The relative proportions and activity of methanogens:SRB have long been of interest but mainly in relation to explaining H<sub>2</sub> disposal<sup>(103)</sup>. Interestingly, Fernandes *et al.*<sup>(104)</sup> have recently confirmed that methane production and carriage of detectable Archaea (mainly methanogens in human subjects) are inversely related to BMI and that methanogenesis appears to allow more efficient production and absorption of SCFA from dietary fibre fermentation. While the ecological processes regulating the relative abundance of gut SRB and methanogens are not fully understood, ingestion of fermentable fibre increases methanogenesis in CH<sub>4</sub>-producing subjects, while sulphate or dietary protein appear to stimulate the numbers of SRB and presumably their metabolic activities within the gut microbiota<sup>(105–109)</sup>.

In a large clinical cohort, Wang *et al.*<sup>(13)</sup> showed in 2011 that plasma concentrations of choline, TMAO and betaine, all metabolites of phosphatidylcholine metabolism, are predictive of CVD. While all three up-regulated multiple macrophage scavenger receptors, choline and TMAO feeding induced arteriosclerosis in mice. Moreover, the authors confirmed the essential role of the gut microbiota in TMAO production from dietary choline in germ-free animals, while broad spectrum antibiotics lowered macrophage cholesterol accumulation, foam cell formation and aortic lesions in high-fat-fed conventional animals. Koeth *et al.*<sup>(14)</sup> more recently showed that another compound, L-carnitine with a TMA structure similar to that of choline and commonly found in meat, may also be converted to TMA by

the gut microbiota and contribute to the increased CVD risk associated with high red meat consumption<sup>(110,111)</sup>. They confirmed microbial involvement in TMA(O) formation from dietary L-carnitine using a stable isotope dilution method and broad spectrum antibiotic microbiota suppression in five healthy omnivorous subjects and in germ-free and antibiotic-treated animals. Conversion of dietary L-carnitine to TMAO did not appear to occur in long-term (>1 year) vegans or vegetarians, suggesting an adoptive response of the gut microbiota in omnivores to TMA production from L-carnitine derived from red meat. Compared with the vegans and vegetarians, omnivores had elevated plasma TMAO concentrations and significantly higher relative abundance of faecal clostridia and peptostreptococci, groups of bacteria commonly associated with protein fermentation. Furthermore, the authors confirmed the direct and dose-dependent association between fasting plasma L-carnitine levels and prevalent coronary artery disease in a large cohort of elective cardiac evaluation subjects (*n* 2595) and elevated L-carnitine was significantly associated with risk of major adverse cardiac events. When corrected for plasma TMAO these associations disappeared suggesting that TMAO mediated disease risk rather than L-carnitine itself. TMAO also impacted on BA metabolism in the liver at multiple levels including cholesterol transporters and suppression of BA synthetic enzymes Cyp7a1 and Cyp27a1 and animals fed TMAO had a significantly lower BA pool compared with those fed standard rodent chow.

These studies have provided a clear pathological mechanism involving the gut microbiota: mammalian co-metabolic processing of choline, phosphatidylcholine and L-carnitine which appears responsive to red meat consumption but which is much reduced or absent in vegetarians on high-fibre diets. This novel mechanism also fits neatly into existing data from epidemiological studies implicating red meat consumption in CVD risk, and whole-plant food or fibre with low risk of CVD. It also fits with the important role of the enterohepatic circulation of BA in regulating cholesterol metabolism and CVD risk via the activities of nuclear receptor FXR $\alpha$  and G-protein-coupled receptor TGR-5 (Fig. 1).

#### *Reducing CVD risk with probiotics*

Probiotics are defined as 'live microorganisms which when administered in adequate amount confer a health benefit on the host' and represent a very direct means of modulating the composition of the gut microbiota by adding exogenous microorganisms<sup>(112)</sup>. The most common probiotics are lactobacilli and bifidobacteria<sup>(113)</sup>. The notion that probiotics may impact on CVD risk stems from early suggestions that yoghurt consumption may reduce blood cholesterol levels in nomadic dairying peoples<sup>(114,115)</sup>. Some studies from the 1970s and 1980s found that cholesterol levels could be reduced following consumption of large volumes of yoghurt or fermented milk<sup>(114–116)</sup>. For example, Mann *et al.*<sup>(115)</sup> found that massive (4 l/d) consumption of milk fermented with a 'wild' strain of *Lactobacillus*,

**Table 1.** Selected studies where recognised probiotic strains, delivered in fermented milk/yoghurt or pure form, have been investigated for cholesterol-lowering effects in hypercholesterolaemic individuals (after<sup>(127)</sup>)

N	Strain(s)	Dose/vehicle	TC	LDL-C	HDL-C	TAG	Reference
29	<i>Lactobacillus acidophilus</i>	200ml FM	↓	NS	↓	–	Anderson & Gilliland <sup>(117)</sup>
32	<i>Enterococcus faecium</i> <i>Streptococcus thermophilus</i>	200ml Yoghurt	↓	↓	NS	NS	Bertolami et al. <sup>(118)</sup>
44	<i>Lactobacillus fermentum</i>	2×capsules	NS	NS	NS	NS	Simons et al. <sup>(119)</sup>
Moderate cholesterol							
14	<i>Lactobacillus acidophilus</i>	300g Yoghurt	↓	NS	NS	NS	Ataie-Jafari et al. <sup>(120)</sup>
18	<i>Bifidobacterium lactis</i> <i>Lactobacillus plantarum</i>	100ml FM	NS	NS	NS	NS	Karlssohn et al. <sup>(121)</sup>
Atherosclerosis							
60	<i>Lactobacillus acidophilus</i> & <i>Bifidobacterium lactis</i>	300g Yoghurt	↓	↓	NS	NS	Eitahed et al. <sup>(122)</sup>
T2D	<i>Lactobacillus reuteri</i>	250g	↓	↓	NS	NS	Jones et al. <sup>(29)</sup>
115	<i>Lactobacillus reuteri</i>	Microencapsulated					
127	<i>Lactobacillus reuteri</i>	2×10 <sup>9</sup> CFU (capsules)	↓	↓	NS	NS	Jones et al. <sup>(30)</sup>
60	3× <i>Lactobacillus plantarum</i>	1.2×10 <sup>8</sup> CFU (capsules)	↓	NS	NS	NS	Fuentes et al. <sup>(122)</sup>
43	<i>Enterococcus faecium M-74</i>	2×10 <sup>9</sup> CFU + 50µg organically bound selenium (capsules)	↓	↓	NS	NS	Hivak et al. <sup>(123)</sup>

CFU, colony forming units; FM, fermented milk; TC, total cholesterol; T2D, type 2 diabetes.

resulted in a significant reduction in serum cholesterol in twenty-four Maasai warriors. However, many of these early studies used milk or pasteurised yoghurt as control, confounding interpretation and also, did not characterise the microorganisms used to ferment the milk to any great extent. Similarly, studies were often conducted in healthy subjects within normal cholesterol ranges who do not alter the cholesterol levels readily in response to dietary change.

Later studies in the 1990s began to recognise that milks fermented with different lactic acid bacteria may elicit different effects (Table 1). For example, Andersson and Gilliland<sup>(117)</sup> found a significant reduction in total cholesterol in fourteen hypercholesterolaemic subjects when consuming *Lactobacillus acidophilus* L1, a human-derived strain, compared with *L. acidophilus* ATCC 43121, isolated from the porcine gut. Agerholm-Larsen et al.<sup>(124)</sup> reported a metanalysis of studies using the probiotic fermented milk Gaiò<sup>®</sup>, containing *Enterococcus faecium* (with the potential probiotic activity) and two strains of *Streptococcus thermophilus* for milk acidification. From six studies using this product, the authors concluded that short-term intake (4–8 weeks) of this fermented milk produced significant lowering of total and LDL-cholesterol (by 4 and 5%, respectively) but that further studies were required to confirm any long-term effects. Hlivak et al.<sup>(125)</sup> more recently, using another strain of *Enterococcus faecium*, M-74 in combination with selenium, found a 12% reduction in serum cholesterol after a 1-year intervention in forty-three volunteers who consumed the probiotic or placebo. Interestingly, not only is this one of the few long-term studies to confirm the cholesterol-lowering effects of probiotics, but it was also conducted with the probiotic in lyophilised powder form delivered in a capsule containing 2×10<sup>9</sup> colony-forming units of

*E. faecium* M-74. The test product however, also contained 50mg/dose of organically bound selenium, which may independently lower serum cholesterol<sup>(126)</sup>. However, many other early studies have also reported no effect of probiotic intervention in lowering serum cholesterol levels. In general, early probiotic studies have rarely been conducted in large cohorts presumably because of costs associated with culture-based faecal microbiology, and seldom reached the statistical power necessary to adequately test the cholesterol-lowering potential of even the most promising strains<sup>(127)</sup>. Moreover, it has become apparent that probiotics or probiotic effects are strain specific with particular probiotic health effects, e.g. immune modulation, production of antimicrobial compounds or the ability to lower cholesterol being present in one strain and absent in another strain belonging even to the same species. A number of mechanisms have been proposed including binding of cholesterol within the gut lumen or incorporation of cholesterol into bacterial cell walls, production of SCFA which might modulate cholesterol synthesis in the liver or increased deconjugation of BA impacting on cholesterol absorption or increasing faecal excretion of bile driving hepatic BA synthesis from circulating cholesterol<sup>(128)</sup>. Although a few of these putative mechanisms have been shown in human subjects, they have been used *in vitro* as screening tools in an attempt to improve probiotic efficacy. Jones et al.<sup>(29)</sup> investigated the ability of a *Lactobacillus reuteri* strain NCIIMB 30242 microencapsulated in a yoghurt formulation to reduce the cholesterol levels in hypercholesterolaemic individuals (*n* 114). Importantly, this strain had been selected as a putative cholesterol-lowering probiotic because of its bile salt hydrolase activity. These authors found that consuming the yoghurt containing the microencapsulated probiotic *L. reuteri* NCIIMB 30242 twice daily for

6 weeks with a combined daily dose of about  $10^{11}$  viable bacteria, decreased serum total cholesterol and LDL-cholesterol by 4.81 and 8.92%, respectively, compared with the placebo. Non-HDL cholesterol and apoB-100 were also significantly reduced compared with the placebo group. In a second study, this time using the same strain in the lyophilised form, the authors confirmed the cholesterol-lowering ability in 127 hypercholesterolaemic individuals<sup>(30)</sup>. Upon probiotic supplementation for 9 weeks, LDL-cholesterol, total cholesterol, non-HDL cholesterol and apoB-100 were significantly reduced by 11.64, 9.14, 11.30 and 8.41%, respectively. Moreover, the subjects receiving the probiotic had lower serum levels of plant sterols, a surrogate marker for cholesterol absorption and higher plasma levels of deconjugated BA, leading the authors to suggest a novel cholesterol-lowering mechanism for this strain through reduced cholesterol absorption via the action of deconjugated BA on hepatic FXR $\alpha$ , a nuclear receptor responsible for controlling lipid absorption from the gut by regulating the expression of lipid transporters on the gut wall. Thus it appears that by right choice of probiotic strain it may be possible to lower CVD risk through improved profiles of disease biomarkers especially plasma cholesterol levels.

#### *Reducing CVD risk with prebiotics*

A certain class of fermentable carbohydrates has been identified as of particular interest for their ability to modulate the relative abundance of gut bacteria considered beneficial for human health. Prebiotics are selectively fermented ingredients that result in specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefit(s) upon host health<sup>(49,129)</sup>. Common prebiotics include the fructans, inulin and oligofructose, lactulose, galatooligosaccharides, arabinogalactan, arabinoxylan, pectic oligosaccharides,  $\beta$ -glucan and resistant starches, all of which have been shown to increase the relative abundance of bifidobacteria within the human gut microbiota<sup>(22)</sup>. Bifidobacteria are a group of bacteria particularly equated with gut health because of their saccharolytic nature, history of use as probiotics and because they dominate the gut microbiota of breastfed infants<sup>(129)</sup>. In parallel, many of these compounds have long been under investigation for their ability to modify blood lipid profiles mainly because of their ability to bind cholesterol or BA in the upper gut and increase sterol excretion, or for some, through their gel-forming nature causing a bulking effect in the intestine and triggering satiety<sup>(130,131)</sup>. Animal studies have consistently shown that dietary intervention with prebiotics, especially the fructans inulin and oligofructose, can reduce serum TAG<sup>(130)</sup>. Elevated TAG, together with elevated total and LDL-cholesterol, low HDL-cholesterol and elevated total cholesterol:HDL-cholesterol characterise dyslipidaemia, and represent an important modifiable risk factor for CVD. Brigenti<sup>(132)</sup> conducted a meta-analysis of human studies investigating the ability of fructans to impact on serum TAG and concluded that 81% of

fifteen trials with inulin or oligofructose reduced serum TAG. Although this effect was small (about 7.5% reduction in serum TAG) and only statistically significant in five of the interventions, the effect appeared to be independent of gender, type of prebiotic, background diet, overweight, dyslipidaemia or diabetes. However, the low number of studies considered in the meta-analysis limited the power to adequately assess the impact of these confounders. More recently, Jackson and Lovegrove<sup>(127)</sup> reviewed the current evidence on the ability of prebiotics (as well as probiotics and synbiotics) to alter blood lipids including cholesterol levels. They found that the majority of prebiotic studies were conducted with either inulin or oligofructose (a hydrolytic product of inulin) and that despite ample evidence for TAG lowering and often cholesterol-lowering effects of prebiotic dietary supplementation in animals, prebiotic trials in human subjects gave favourable if inconsistent modulation in lipid levels<sup>(127)</sup>. Table 2 summarises dietary intervention studies in human subjects with recognised prebiotics<sup>(127)</sup>. Although eight out of the twenty-one studies showed that prebiotic intervention did not change the blood lipids levels, the remainder showed statistically significant lowering of lipid biomarkers of CVD risk, usually TAG and/or total cholesterol. Although, prebiotics appeared to be more efficacious in the hyperlipidaemic, more studies are needed in the specific target groups, especially those fulfilling the criteria for the metabolic syndrome and in the obese. Fermentation of prebiotics, as with other fermentable fibres, leads to the production of SCFA. Demigné *et al.*<sup>(153)</sup> showed that *in vitro*, propionate was an efficient inhibitor of cholesterol biosynthesis in rat hepatocytes when acetate was the main substrate available. This *in vitro* observation was confirmed later *in vivo*. However, acetate only becomes the main substrate for cholesterol biosynthesis in the liver when animals are fed high-fibre diets. This indicates that SCFA produced during high fibre diets are unlikely to increase circulating cholesterol levels despite increasing availability of the substrate for cholesterol<sup>(127)</sup>. This explains also why prebiotic interventions do not always lead to lower cholesterol in human studies, as hepatic cholesterol biosynthesis from acetate in human subjects, especially those on a low fibre, high-fat Western-style diet, is likely to contribute very little to circulating cholesterol levels<sup>(127)</sup>. Kok *et al.*<sup>(154)</sup> showed that oligofructose induces the gut hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 of rats fed normal chow and that this contributed to improved glucose homeostasis and lipid metabolism. Glucose-dependent insulinotropic polypeptide induces insulin and stimulates lipoprotein lipase in adipocytes, while glucagon-like peptide-1 stimulates insulin secretion, improves insulin sensitivity and contributes to satiety by reducing gastric emptying. More recently, Cani *et al.*<sup>(19)</sup> have shown that the prebiotic oligofructose can reverse metabolic endotoxemia by reducing gut permeability and LPS leakage into circulation. They also proposed the term 'metabolic endotoxemia' to describe the chronic low-grade systemic inflammation characteristic of obesity and type 2 diabetes<sup>(16)</sup>. Improved gut

**Table 2.** Dietary interventions investigating the ability of common prebiotics (inulin, oligofructose/fructooligosaccharides and galactooligosaccharides) to improve blood lipid profiles in human subjects (after<sup>(127,132)</sup>)

Subjects	n	Prebiotic dose	Design	Result	Reference
Normolipidaemic	12	9g/d, Inulin, 4 weeks	Sequential	↓ TAG, ↓ TC	Brighenti <i>et al.</i> <sup>(133)</sup>
	12	20g/d, scFOS, 4 weeks	Crossover	NS	Luo <i>et al.</i> <sup>(134)</sup>
	66	14g/d, Inulin, 4 weeks	Crossover	NS	Pedersen <i>et al.</i> <sup>(135)</sup>
	11	Up to 34g/d, Inulin 9 weeks	Parallel	NS	Kruse <i>et al.</i> <sup>(136)</sup>
	12	15g/d Inulin, FOS or GOS, 3 weeks	Crossover	NS	Van Dokkum <i>et al.</i> <sup>(137)</sup>
Normolipidaemic elderly	54	10g/d, Inulin, 8 weeks	Parallel	↓TAG ↓ Insulin	Jackson <i>et al.</i> <sup>(138)</sup>
	12	20g/d, 3 weeks	Crossover	↓TAG	Causesy <i>et al.</i> <sup>(139)</sup>
	8	10g/d Inulin, 3 weeks	Crossover	↑TAG, ↓ hepatic lipogenesis	Letexier <i>et al.</i> <sup>(140)</sup>
	22	11 g/d Inulin enriched pasta, 5 weeks	Crossover	↑HDL-C, ↓ TAG, ↓ TC/HDL-C, ↓ LpA	Russo <i>et al.</i> <sup>(141)</sup>
	17	10g/d Syn1, 6m	Crossover	NS	Forcheron <i>et al.</i> <sup>(142)</sup>
Hyperlipidaemic	44	5.5-g/d, B-GOS, 10 weeks	Crossover	NS	Vulevic <i>et al.</i> <sup>(143)</sup>
	10	5-10g/d, FOS, 3 weeks	Parallel	↓ TC	Yen <i>et al.</i> <sup>(144)</sup>
	46	8g/d, 5 weeks	Parallel	↓ TC	Hidaka <i>et al.</i> <sup>(145)</sup>
	25	18g/d, Inulin, 6 weeks	Crossover	↓ LDL-C, ↓ TC	Davidson <i>et al.</i> <sup>(146)</sup>
	30	10.6g/d, scFOS, 8 weeks	Crossover	NS	Giacco <i>et al.</i> <sup>(147)</sup>
Type 2 diabetes	18	8g/d, OFS 2 weeks	Parallel	↓LDL-C, ↓ TC ↓ Gluc	Yamashita <i>et al.</i> <sup>(148)</sup>
	20	15g/d, OFS, 3 weeks	Crossover	NS	Alles <i>et al.</i> <sup>(149)</sup>
	12	7g/d, Inulin, 4 weeks	Parallel	↓ vLDL, ↓ TC, ↓ LDL, ↓ TAG	Balcázar-Muñoz <i>et al.</i> <sup>(150)</sup>
Dyslipidaemic obese	35	0.14g/kg body wt/d, FOS, 12 weeks	Parallel	↓LDL-C	Genta <i>et al.</i> <sup>(151)</sup>
	45	5.5-g/d, B-GOS, 12 weeks	Crossover	↓ TC ↓ TAG ↑ TC:HDL-C	Vulevic <i>et al.</i> <sup>(152)</sup>

TC, total cholesterol; FOS, fructooligosaccharides; scFOS, short-chain FOS; OFS, oligofructose; GOS, galactooligosaccharides; B-GOS, Bifidum GOS; Gluc, glucose; LpA, lipoprotein(a).

barrier activity resulted from prebiotic induction of the gut hormone glucagon-like peptide-2, a result confirmed in a later animal experiment<sup>(78)</sup>. More recently, Everard *et al.*<sup>(155)</sup> confirmed Cani's earlier work that the prebiotic oligofructose could reduce gut permeability and associated metabolic endotoxemia and obesity in high-fat-fed animals through induction of intestinal endocannabinoids. They also found that prebiotic oligofructose-induced microbiota modulation also resulted in increased relative abundance of *Akkermansia muciniphila*, a mucus dwelling and degrading intestinal commensal. The authors found that the same physiological effects could be brought about by ingestion of *Ak. muciniphila* alone as a 'probiotic', but that the effect depended on microbial viability.

However, it must be emphasised that it is often difficult to extrapolate animal data to the human situation, where the genetic background is much more diverse, diets are open and vary greatly between individuals and where other life-style factors are sometimes not reported or underreported (e.g. alcohol intake, drugs and smoking, and high fat, high sugar convenience foods). Moreover, the quantities of prebiotic used in animal studies targeting metabolic disease and cholesterol are much higher than those routinely used in human dietary interventions. 10% w/w is the typical dose used in mouse studies and equates to more than 50 g/d prebiotic for human subjects, using mean European adult male body weight<sup>(156)</sup>. Interestingly, this level of fermentable fibre intake in

human subjects correlates well with estimates of dietary fibre intake for ancient diets and traditional high-fibre diets in the Mediterranean, Africa and China<sup>(31)</sup>.

#### *Reducing CVD risk with whole-grain cereals: oats as a case study*

Whole-grain cereals, and in particular oats and fibre fractions derived from oats, have long been considered as foods capable of reducing CVD risk by lowering blood cholesterol levels. Whole-grain oats comprise a number of different classes of biologically active molecule capable of modulating cholesterol metabolism in mammals, including mono- and di-unsaturated fatty acids, fibres such as β-glucan, arabinoxylans and resistant starch, phenolic compounds such as dehydroferulates and avenanthramides, and lignans which are converted into the phytoestrogens enterolactone and enterodiol by gut bacteria<sup>(157,158)</sup>. However, early studies attributed the cholesterol-lowering effect of oats to their gel-forming nature within the gut and/or cholesterol/BA binding. β-Glucan is the major structural polysaccharides accounting for about 85% of oat cell wall and is a soluble fibre, which, depending on molecular length, forms viscous gels in aqueous solutions. Tiwari and Cummins<sup>(159)</sup> performed a recent metanalysis on the ability of β-glucans to reduce blood cholesterol and glucose

levels. Considering 126 clinical studies with different doses of  $\beta$ -glucans from either oats or barley, the authors concluded that there was a significant inverse relationship between  $\beta$ -glucan intake and blood total cholesterol, LDL-cholesterol and TAG levels. Moreover, there was a significant dose–response between  $\beta$ -glucan ingestion and cholesterol-lowering activity, with 3 g/d of either oat or barley  $\beta$ -glucan being sufficient to lower blood total cholesterol (by  $-0.30$  mm).  $\beta$ -Glucan from either oats or barley are one of the few fibres to have attained health claims status with the European Food Safety Authority<sup>(160)</sup>. While the ability of oats and  $\beta$ -glucans to increase excretion of BA and cholesterol in faeces appears to be well established in the literature, the underlying mechanism still remains to be determined.  $\beta$ -Glucans have been proposed to alter the viscosity of the unstirred layer lining the intestinal mucosa thus reducing the flow of BA towards the epithelial cell surface and reducing BA/cholesterol absorption. The gel-forming nature of  $\beta$ -glucans has been suggested to trap BA/cholesterol micelles thereby reducing the efficiency of cholesterol absorption, and finally,  $\beta$ -glucans, especially those of small molecular weight, have been suggested to bind BA, directly inhibiting their reabsorption in the small intestine and driving them distally into the colon where they are deconjugated/hydrolysed by the resident microbiota<sup>(161)</sup>. Whether one or all of these mechanisms holds is still a matter of debate. However, other possibilities also exist, not least the ability of oats or  $\beta$ -glucan to impact on the gut microbiota and their metabolic activities. Andersson *et al.*<sup>(162)</sup> investigated the ability of oat bran (27%) to lower blood cholesterol in two substrains of C57BL/6 mice on atherogenic diet (low choline diet), the C57BL/6 NCrI and the C57BL/6JBomTac strains, compared with control fibres. In the C57BL/6 NCrI mice, dietary intervention with oat bran reduced blood cholesterol with a concomitant increase in faecal BA excretion and increased hepatic BA synthesis. No change in cholesterol, BA excretion or synthesis was observed in the C57BL/6JBomTac. However, the C57BL/6JBomTac mice carried significantly lower intestinal populations of *Enterobacteriaceae*, *Akkermansia* and *Bacteroides fragilis* than the C57BL/6 NCrI mice, and changes within the relative abundance of the gut microbiota appeared to predict cholesterol response to oat bran. This *in vivo* experiment suggests that the gut microbiota play a critical role in the cholesterol-lowering ability of oat bran. *In vitro* we have shown that different oat preparations can mediate a prebiotic modulation of the human gut microbiota, giving significant increases in bifidobacteria, lactobacilli and SCFA<sup>(163–167)</sup>. We also showed that  $\beta$ -glucan increases the relative abundance of bifidobacteria in C57BL/6 mice fed high-fat diet, and regulates food intake by suppressing neuronal signals in appetite centres of the brain<sup>(20)</sup>. The BA sequestrant, colestyramine has been shown to trigger satiety via reduced gastric emptying in healthy human subjects<sup>(168)</sup>, suggesting that factors controlling the enterohepatic circulation of BA may contribute to satiety as well as regulating blood cholesterol levels. Interestingly, recent studies showing that probiotic

microorganisms can reduce cholesterol uptake from the intestine via modulation of BA signalling, discussed earlier<sup>(29,30)</sup> raise another possibility that oats and prebiotics in general (including certain polyphenols) may selectively stimulate gut bacteria capable of hydrolysing bile salts modifying the enterohepatic circulation of BA both in terms of quantity and chemical profile<sup>(39,79,169–171)</sup>. Intestinal lactobacilli and bifidobacteria commonly encode bile salt hydrolysing enzymes and changes in their relative abundance wrought by probiotics, prebiotics and polyphenols could increase also their relative contribution to modifying the pool of BA returning from the gut and acting as signalling molecules in the liver, the gut wall and systemically through receptors FXR $\alpha$  and TGR-5 to impact on lipid absorption from the intestine, lipid and glucose homeostasis, thermogenesis and inflammation<sup>(30,80,146,148,149)</sup>.

### Conclusion

New observations on how diet shapes both the composition and metabolic output of the gut microbiota place developments in probiotics and prebiotics into an anthropological setting, establishing a scientific rationale for efficacious functional food design. Foods long known to be protective against CVD are emerging as efficacious microbiota modulators and suggest that diets high in fruit, vegetables and whole-grain cereals inherently rich in fermentable fibres, prebiotics and polyphenols may mediate at least some of their beneficial activities through the gut microbiota. Conversely, high-fat, high red meat and low-fibre diets, are associated with reduced microbiota diversity, increased relative abundance of undesirable microorganisms and increased production of toxic compounds including the cardiotoxicant TMAO. These observations raise the intriguing possibility that gut microbiome interactions with whole-plant foods, probiotics and prebiotics may be at the base of healthy eating pyramids advised by regulatory agencies across the globe, as summarised in Fig. 1. Moreover, recent studies showing that probiotic bacteria through modulation of the enterohepatic circulation of BA can raise plasma unconjugated BA concentrations and concomitantly reduce lipid absorption from the intestine and reduce blood cholesterol levels, suggests at least one unifying theory of probiotic, prebiotic and polyphenol mode of action, through BA sequestration and modified microbiota derived BA profiles and regulation of nuclear receptors such as FXR $\alpha$  and G-protein-coupled receptors such as TGR-5. These important physiological signalling molecules have been implicated in many aspects of CVD risk including BA, cholesterol and glucose homeostasis, inflammation and arterial function. Taken together these observations suggest that at least one way to heart health may be through modulation of the gut microbiome.

### Acknowledgements

The authors would like to thank the Nutrition Society and Royal Society of Medicine for allowing the corresponding author to present this paper at their Joint

Winter Meeting on 'Dietary Strategies for the Management of Cardiovascular Risk', December 11–12, 2012, London, UK. In particular, we would like to sincerely thank the Organising and Scientific Committees especially Professor Julie Lovegrove, University of Reading.

#### Financial support

This paper was not supported by external finance.

#### Conflicts of interest

None.

#### Authorship

K. M. T. was the lead author and involved in all aspects of the review. F. F. and R. V. contributed to writing and editing the article, scientific content, presentation style and preparing the artwork.

#### References

1. Gensini GF, Comeglio M & Colella A (1988) Classical risk factors and emerging elements in the risk profile for coronary artery disease. *Eur Heart J* **19**, Suppl. A, A53–A61.
2. Negi S & Anand A (2010) Atherosclerotic coronary heart disease-epidemiology, classification and management. *Cardiovasc Hematol Disord Drug Targets* **10**, 257–261.
3. Ley RE, Turraugh PJ, Klein S *et al.* (2006) Microbial ecology: human gut microbes associated with obesity. *Nature* **444**, 1022–1023.
4. Giongo A, Gano KA, Crabb DB *et al.* (2011) Toward defining the autoimmunity microbiome for type 1 diabetes. *ISME J* **5**, 82–91.
5. Brown CT, Davis-Richardson AG, Giongo A *et al.* (2011) Gut microbiome metagenomics analysis suggests a functional model for the development of autoimmunity for type 1 diabetes. *PLoS ONE* **6**, e25792.
6. de Goffau MC, Luopajarvi K, Knip M *et al.* (2013) Fecal microbiota composition differs between children with  $\beta$ -cell autoimmunity and those without. *Diabetes* **62**, 1238–1244.
7. Larsen N, Vogensen FK, van den Berg FW *et al.* (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. *PLoS ONE* **5**, e9085.
8. Zhu L, Baker SS, Gill C *et al.* (2013) Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. *Hepatology* **57**, 601–609.
9. Sanapareddy N, Legge RM, Jovov B *et al.* (2012) Increased rectal microbial richness is associated with the presence of colorectal adenomas in humans. *ISME J* **6**, 1858–1868.
10. Markle JG, Frank DN, Mortin-Toth S *et al.* (2013) Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. *Science* **339**, 1084–1088.
11. Bäckhed F, Ding H, Wang T *et al.* (2004) The gut microbiota as an environmental factor that regulates fat storage. *Proc Natl Acad Sci USA* **101**, 15718–15723.
12. Vrieze A, Van Nood E, Holleman F *et al.* (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. *Gastroenterology* **143**, 913–916.e7.
13. Wang Z, Klipfell E, Bennett BJ *et al.* (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature* **472**, 57–63.
14. Koeth RA, Wang Z, Levison BS *et al.* (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. *Nat Med* **19**, 576–585.
15. Conterno L, Fava F, Viola R *et al.* (2011) Obesity and the gut microbiota: does up-regulating colonic fermentation protect against obesity and metabolic disease? *Genes Nutr* **6**, 241–260.
16. Cani PD, Amar J, Iglesias MA *et al.* (2007) Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes* **56**, 1761–1772.
17. Zhang C, Zhang M, Wang S *et al.* (2010) Interactions between gut microbiota, host genetics and diet relevant to development of metabolic syndromes in mice. *ISME J* **4**, 232–241.
18. Fava F, Gitau R, Griffin BA *et al.* (2013) The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome 'at-risk' population. *Int J Obes (Lond)* **37**, 216–223.
19. Cani PD, Neyrinck AM, Fava F *et al.* (2007) Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. *Diabetologia* **50**, 2374–2383.
20. Arora T, Loo RL, Anastasovska J *et al.* (2012) Differential effects of two fermentable carbohydrates on central appetite regulation and body composition. *PLoS ONE* **7**, e43263.
21. Anastasovska J, Arora T, Sanchez Canon GJ *et al.* (2012) Fermentable carbohydrate alters hypothalamic neuronal activity and protects against the obesogenic environment. *Obesity (Silver Spring)* **20**, 1016–1023.
22. Tuohy KM, Brown DT & Klinder A (2010) Shaping the human microbiome with prebiotic foods – current perspectives for continued development. *Food Sci Technol Bull: Funct Foods* **7**, 49–64.
23. Wollever TM (1997) Workshop report. Fiber and CHD management. *Adv Exp Med Biol* **427**, 315–317.
24. Delzenne NM & Williams CM (2002) Prebiotics and lipid metabolism. *Curr Opin Lipidol* **13**, 61–67.
25. Jenkins DJ, Kendall CW, Axelsen M *et al.* (2000) Viscous and nonviscous fibres, nonabsorbable and low glycaemic index carbohydrates, blood lipids and coronary heart disease. *Curr Opin Lipidol* **11**, 49–56.
26. Fava F, Lovegrove JA, Gitau R *et al.* (2006) The gut microbiota and lipid metabolism: implications for human health and coronary heart disease. *Curr Med Chem* **13**, 3005–3021.
27. Toeller M, Buyken AE, Heitkamp G *et al.* (1999) Fiber intake, serum cholesterol levels, and cardiovascular disease in European individuals with type 1 diabetes. EURODIAB IDDM Complications Study Group. *Diabetes Care* **22**, Suppl. 2, B21–B28.
28. Ludwig DS, Pereira MA, Kroenke CH *et al.* (1999) Dietary fiber, weight gain, and cardiovascular disease risk factors in young adults. *JAMA* **282**, 1539–1546.
29. Jones ML, Martoni CI, Parent M *et al.* (2012) Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-active *Lactobacillus reuteri* NCIMB 30242

- yoghurt formulation in hypercholesterolaemic adults. *Br J Nutr* **107**, 1505–1513.
30. Jones ML, Martoni CJ & Prakash S (2012) Cholesterol lowering and inhibition of sterol absorption by *Lactobacillus reuteri* NCIMB 30242: a randomized controlled trial. *Eur J Clin Nutr* **66**, 1234–1241.
  31. Tuohy KM, Gougoulis C, Shen Q *et al.* (2009) Studying the human gut microbiota in the trans-omics era – focus on metagenomics and metabonomics. *Curr Pharm Des* **15**, 1415–1427.
  32. Flint HJ, Scott KP, Louis P *et al.* (2012) The role of the gut microbiota in nutrition and health. *Nat Rev Gastroenterol Hepatol* **9**, 577–589.
  33. Lepage P, Leclerc MC, Joossens M *et al.* (2013) A metagenomic insight into our gut's microbiome. *Gut* **62**, 146–158.
  34. Ouwehand A, Isolauri E & Salminen S (2002) The role of the intestinal microflora for the development of the immune system in early childhood. *Eur J Nutr* **41**, Suppl. 1, I32–I37.
  35. Fava F & Danese S (2011) Intestinal microbiota in inflammatory bowel disease: friend or foe? *World J Gastroenterol* **17**, 557–566.
  36. Mulder IE, Schmidt B, Lewis M *et al.* (2011) Restricting microbial exposure in early life negates the immune benefits associated with gut colonization in environments of high microbial diversity. *PLoS ONE* **6**, e28279.
  37. Hand T & Belkaid Y (2010) Microbial control of regulatory and effector T cell responses in the gut. *Curr Opin Immunol* **22**, 63–72.
  38. Zhou P, Ten S, Sinha S *et al.* (2008) Insulin receptor autoimmunity and insulin resistance. *J Pediatr Endocrinol Metab* **21**, 369–375.
  39. Nokoff N & Rewers M (2013) Pathogenesis of type 1 diabetes: lessons from natural history studies of high-risk individuals. *Ann N Y Acad Sci* **1281**, 1–15.
  40. Carbone F, Nencioni A, Mach F *et al.* (2013) Evidence on the pathogenic role of auto-antibodies in acute cardiovascular diseases. *Thromb Haemost* **109**, 854–868.
  41. Fetissov SO, Hamze Sinno M, Coëffier M *et al.* (2008) Autoantibodies against appetite-regulating peptide hormones and neuropeptides: putative modulation by gut microflora. *Nutrition* **24**, 348–359.
  42. Proal AD, Albert PJ & Marshall T (2009) Autoimmune disease in the era of the metagenome. *Autoimmun Rev* **8**, 677–681.
  43. Gill SR, Pop M, Deboy RT *et al.* (2006) Metagenomic analysis of the human distal gut microbiome. *Science* **312**, 1355–1359.
  44. Clifford MN (2004) Diet-derived phenols in plasma and tissues and their implications for health. *Planta Med* **70**, 1103–1114.
  45. Lu MF, Xiao ZT & Zhang HY (2013) Where do health benefits of flavonoids come from? Insights from flavonoid targets and their evolutionary history. *Biochem Biophys Res Commun* **434**, 701–704.
  46. Tzounis X, Rodriguez-Mateos A, Vulevic J *et al.* (2011) Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. *Am J Clin Nutr* **93**, 62–72.
  47. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M *et al.* (2012) Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. *Am J Clin Nutr* **95**, 1323–1334.
  48. Natella F, Macone A, Ramberti A *et al.* (2011) Red wine prevents the postprandial increase in plasma cholesterol oxidation products: a pilot study. *Br J Nutr* **105**, 1718–1723.
  49. Petschow B, Doré J, Hibberd P *et al.* (2013) Probiotics, prebiotics, and the host microbiome: the science of translation. *Ann N Y Acad Sci* **1306**, 1–17.
  50. Willcox DC, Willcox BJ, Todoriki H *et al.* (2009) The Okinawan diet: health implications of a low-calorie, nutrient-dense, antioxidant-rich dietary pattern low in glycemic load. *J Am Coll Nutr* **28**, Suppl., 500S–516S.
  51. Moore WE & Holdeman LV (1974) Human fecal flora: the normal flora of 20 Japanese-Hawaiians. *Appl Microbiol* **27**, 961–979.
  52. Koornhof HJ, Richardson NJ, Wall DM *et al.* (1979) Fecal bacteria in South African rural blacks and other population groups. *Isr J Med Sci* **15**, 335–340.
  53. Benno Y, Suzuki K, Suzuki K *et al.* (1986) Comparison of the fecal microflora in rural Japanese and urban Canadians. *Microbiol Immunol* **30**, 521–532.
  54. Moore WE & Moore LH (1995) Intestinal floras of populations that have a high risk of colon cancer. *Appl Environ Microbiol* **61**, 3202–3207.
  55. De Filippo C, Cavalieri D, Di Paola M *et al.* (2010) Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc Natl Acad Sci USA* **107**, 14691–14696.
  56. Schwiertz A, Taras D, Schäfer K *et al.* (2010) Microbiota and SCFA in lean and overweight healthy subjects. *Obesity (Silver Spring)* **18**, 190–195.
  57. Borthakur A, Priyamvada S, Kumar A *et al.* (2012) A novel nutrient sensing mechanism underlies substrate-induced regulation of monocarboxylate transporter-1. *Am J Physiol Gastrointest Liver Physiol* **303**, G1126–G1133.
  58. Gonçalves P, Catarino T, Gregório I *et al.* (2012) Inhibition of butyrate uptake by the primary bile salt chenodeoxycholic acid in intestinal epithelial cells. *J Cell Biochem* **113**, 2937–2947.
  59. Teixeira TF, Grześkowiak Ł, Franceschini SC *et al.* (2013) Higher level of faecal SCFA in women correlates with metabolic syndrome risk factors. *Br J Nutr* **109**, 914–919.
  60. Yatsunenkov T, Rey FE, Manary MJ *et al.* (2012) Human gut microbiome viewed across age and geography. *Nature* **486**, 222–227.
  61. U.S. Department of Agriculture and U.S. Department of Health and Human Services (2012) Dietary guidelines for Americans. <http://www.cnpp.usda.gov/Publications/DietaryGuidelines/2010/PolicyDoc/PolicyDoc.pdf>
  62. Food Standards Agency, U.K. (2011) Eat Well Plate. <http://www.food.gov.uk/scotland/scotnut/eatwellplate/>
  63. Jacobs DR Jr, Meyer KA, Kushi LH *et al.* (1999) Is whole grain intake associated with reduced total and cause-specific death rates in older women? The Iowa Women's Health Study. *Am J Public Health* **89**, 322–329.
  64. Liu S, Manson JE, Lee IM *et al.* (2000) Fruit and vegetable intake and risk of cardiovascular disease: the Women's Health Study. *Am J Clin Nutr* **72**, 922–928.
  65. Joshupura KJ, Hu FB, Manson JE *et al.* (2001) The effect of fruit and vegetable intake on risk for coronary heart disease. *Ann Intern Med* **134**, 1106–1114.
  66. Mellen PB, Walsh TF, Herrington DM (2008) Whole grain intake and cardiovascular disease: a meta-analysis. *Nutr Metab Cardiovasc Dis* **18**, 283–290.
  67. He M, van Dam RM, Rimm E *et al.* (2010) Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. *Circulation* **121**, 2162–2168.

68. Ye EQ, Chaacko SA, Chou EL *et al.* (2012) Greater whole-grain intake is associated with lower risk of type 2 diabetes, cardiovascular disease, and weight gain. *J Nutr* **142**, 1304–1313.
69. European Food Safety Authority (2010) Scientific opinion on establishing food-based dietary guidelines. EFSA J **8**:1460 [42 pp.]. <http://www.efsa.europa.eu/en/efsajournal/pub/1460.htm>
70. Del Rio D, Rodriguez-Mateos A, Spencer JP *et al.* (2013) Dietary (poly)phenolics in human health: structures, bio-availability, and evidence of protective effects against chronic diseases. *Antioxid Redox Signal* **18**, 1818–1892.
71. Costabile A, Klinder A, Fava F *et al.* (2008) Whole-grain wheat breakfast cereal has a prebiotic effect on the human gut microbiota: a double-blind, placebo-controlled, crossover study. *Br J Nutr* **99**, 110–120.
72. Lin HV, Frassetto A, Kowalik EJ Jr *et al.* (2012) Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. *PLoS ONE* **7**, e35240.
73. Tappenden KA, Albin DM, Bartholome AL *et al.* (2003) Glucagon-like peptide-2 and short-chain fatty acids: a new twist to an old story. *J Nutr* **133**, 3717–3720.
74. Cani PD, Possemiers S, Van de Wiele T *et al.* (2009) Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. *Gut* **58**, 1091–1103.
75. Xiong Y, Miyamoto N, Shibata K *et al.* (2004) Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. *Proc Natl Acad Sci USA* **101**, 1045–1050.
76. Al-Lahham S, Roelofsen H, Rezaee F *et al.* (2012) Proportion acid affects immune status and metabolism in adipose tissue from overweight subjects. *Eur J Clin Invest* **42**, 357–364.
77. Gao Z, Yin J, Zhang J *et al.* (2009) Butyrate improves insulin sensitivity and increases energy expenditure in mice. *Diabetes* **58**, 1509–1517.
78. Jones BV, Begley M, Hill C *et al.* (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. *Proc Natl Acad Sci USA* **105**, 13580–13585.
79. Jones ML, Tomaro-Duchesneau C, Martoni CJ *et al.* (2013) Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. *Expert Opin Biol Ther* **13**, 631–642.
80. Charach G, Grosskopf I, Rabinovich A *et al.* (2011) The association of bile acid excretion and atherosclerotic coronary artery disease. *Thromb Adv Gastroenterol* **4**, 95–101.
81. Matsubara T, Li F & Gonzalez FJ (2013) FXR signaling in the enterohepatic system. *Mol Cell Endocrinol* **368**, 17–29.
82. Kay RM & Truswell AS (1977) Effect of citrus pectin on blood lipids and fecal steroid excretion in man. *Am J Clin Nutr* **30**, 171–175.
83. Marlet JA, Hosig KB, Vollandorf NW *et al.* (1994) Mechanism of serum cholesterol reduction by oat bran. *Hepatology* **20**, 1450–1457.
84. Sembreres S, Dongowski G, Mehriänder K *et al.* (2006) Physiological effects of extraction juices from apple, grape, and red beet pomaces in rats. *J Agric Food Chem* **54**, 10269–10280.
85. Cyphert HA, Ge X, Kohan AB *et al.* (2012) Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. *J Biol Chem* **287**, 25123–25138.
86. Li F, Patterson AD, Krausz KW *et al.* (2012) Metabonomics reveals an essential role for peroxisome proliferator-activated receptor  $\alpha$  in bile acid homeostasis. *J Lipid Res* **53**, 1625–1635.
87. Watanabe M, Morimoto K, Houten SM *et al.* (2012) Bile acid binding resin improves metabolic control through the induction of energy expenditure. *PLoS ONE* **7**, e38286.
88. Sayin SI, Wahlström A, Felin J *et al.* (2013) Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-nuricholic acid, a naturally occurring FXR antagonist. *Cell Metab* **17**, 225–235.
89. Barrett E, Ross RP, O'Toole PW *et al.* (2012)  $\gamma$ -Aminobutyric acid production by culturable bacteria from the human intestine. *J Appl Microbiol* **113**, 411–417.
90. Tian J, Dang HN, Yong J *et al.* (2011) Oral treatment with  $\gamma$ -aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. *PLoS ONE* **6**, e25338.
91. D'Amico MR, Mattarelli P, Biavati B *et al.* (2012) The potential of bifidobacteria as a source of natural folate. *J Appl Microbiol* **112**, 975–984.
92. Pompei A, Cordisco L, Amaretti A *et al.* (2007) Administration of folate-producing bifidobacteria enhances folate status in Wistar rats. *J Nutr* **137**, 2742–2746.
93. Wall R, Ross RP, Shanahan F *et al.* (2009) Metabolic activity of the enteric microbiota influences the fatty acid composition of murine and porcine liver and adipose tissues. *Am J Clin Nutr* **89**, 1393–1401.
94. Wall R, Ross RP, Shanahan F *et al.* (2010) Impact of administered bifidobacterium on murine host fatty acid composition. *Lipids* **45**, 429–436.
95. Tricon S, Burdge GC, Williams CM *et al.* (2005) The effects of conjugated linoleic acid on human health-related outcomes. *Proc Nutr Soc* **64**, 171–182.
96. Pfeuffer M, Fieldtz K, Laue C *et al.* (2011) CLA does not impair endothelial function and decreases body weight as compared with safflower oil in overweight and obese male subjects. *J Am Coll Nutr* **30**, 19–28.
97. al-Waiz M, Milkov M, Michail SC *et al.* (1992) The exogenous origin of trimethylamine in the mouse. *Metabolism* **41**, 135–136.
98. Kotesh A & Mae Diehl A (2002) Animal models of steatohepatitis. *Best Pract Res Clin Gastroenterol* **16**, 79–90.
99. Dunas ME, Barton RH, Toye A *et al.* (2006) Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. *Proc Natl Acad Sci USA* **103**, 12511–12516.
100. Deplancke B, Finster K, Graham WV *et al.* (2003) Gastrointestinal and microbial responses to sulfate-supplemented drinking water in mice. *Exp Biol Med (Maywood)* **228**, 424–433.
101. Carbonero F, Benefiel AC & Gaskins HR (2012) Contributions of the microbial hydrogen economy to colonic homeostasis. *Nat Rev Gastroenterol Hepatol* **9**, 504–518.
102. Gracian S & Balskus EP (2012) Microbial conversion of choline to trimethylamine requires a glycol radical enzyme. *Proc Natl Acad Sci USA* **109**, 21307–21312.
103. Gibson GR, Cummings JH & Macfarlane GT (1988) Competition for hydrogen between sulphate-reducing bacteria and methanogenic bacteria from the human large intestine. *J Appl Bacteriol* **65**, 241–247.
104. Fernandes J, Wang A, Su W *et al.* (2013) Age, dietary fiber, breath methane, and fecal short chain fatty acids

- are interrelated in archaea-positive humans. *J Nutr* **143**, 1269–1275.
105. Christl SU, Gibson GR & Cummings JH (1992) Role of dietary sulphate in the regulation of methanogenesis in the human large intestine. *Gut* **33**, 1234–1238.
106. Christl SU, Murgatroyd PR, Gibson GR *et al.* (1992) Production, metabolism, and excretion of hydrogen in the large intestine. *Gastroenterology* **102**, 1269–1277.
107. Mills DJ, Tuohy KM, Booth J *et al.* (2008) Dietary glycated protein modulates the colonic microbiota towards a more detrimental composition in ulcerative colitis patients and non-ulcerative colitis subjects. *J Appl Microbiol* **105**, 706–714.
108. Kerr BJ, Weber TE, Ziemer CJ *et al.* (2011) Effect of dietary inorganic sulfur level on growth performance, fecal composition, and measures of inflammation and sulfate-reducing bacteria in the intestine of growing pigs. *J Anim Sci* **89**, 426–437.
109. Khalil NA, Walton GE, Gibson GR *et al.* (2013) In vitro batch cultures of gut microbiota from healthy and ulcerative colitis (UC) subjects suggest that sulphate-reducing bacteria levels are raised in UC and by a protein-rich diet. *Int J Food Sci Nutr* (Epublication ahead of print).
110. Bernstein AM, Sun Q, Hu FB *et al.* (2010) Major dietary protein sources and risk of coronary heart disease in women. *Circulation* **122**, 876–883.
111. Micha R, Michas G & Mozaffarian D (2012) Unprocessed red and processed meats and risk of coronary artery disease and type 2 diabetes – an updated review of the evidence. *Curr Atheroscler Rep* **14**, 515–524.
112. Joint FAO/WHO Working Group report on Drafting Guidelines for the Evaluation of Probiotics in Food. London, Ontario, Canada (2002). [http://www.who.int/foodsafety/fs\\_management/en/probiotic\\_guidelines.pdf](http://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf)
113. Tuohy KM, Probert HM, Smejkal CW *et al.* (2003) Using probiotics and prebiotics to improve gut health. *Drug Discov Today* **8**, 692–700.
114. Hepner G, Fried R, St Jeor S *et al.* (1979) Hypocholesterolemic effect of yogurt and milk. *Am J Clin Nutr* **32**, 19–24.
115. Mann GV, Spoerry A, Gray M *et al.* (1972) Atherosclerosis in the Masai. *Am J Epidemiol* **95**, 26–37.
116. Rossouw JE, Burger EM, Van der Vyver P *et al.* (1981) The effect of skim milk, yoghurt, and full cream milk on human serum lipids. *Am J Clin Nutr* **34**, 351–356.
117. Anderson JW & Gilliland SE (1999) Effect of fermented milk (yogurt) containing *Lactobacillus acidophilus* L1 on serum cholesterol in hypercholesterolemic humans. *J Am Coll Nutr* **18**, 43–50.
118. Bertolami MC, Faludi AA & Batlouni M (1999) Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. *Eur J Clin Nutr* **53**, 97–101.
119. Simons LA, Amansec SG & Conway P (2006) Effect of *Lactobacillus fermentum* on serum lipids in subjects with elevated serum cholesterol. *Nutr Metab Cardiovasc Dis* **16**, 531–535.
120. Ataie-Jafari A, Larijani B, Alavi Majd H *et al.* (2009) Cholesterol-lowering effect of probiotic yogurt in comparison with ordinary yogurt in mildly to moderately hypercholesterolemic subjects. *Ann Nutr Metab* **54**, 22–27.
121. Karlsson C, Ahrné S, Molin G *et al.* (2010) Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. *Atherosclerosis* **208**, 228–233.
122. Ejtahed HS, Mohtadi-Nia J, Homayouni-Rad A *et al.* (2011) Effect of probiotic yogurt containing *Lactobacillus acidophilus* and *Bifidobacterium lactis* on lipid profile in individuals with type 2 diabetes mellitus. *J Dairy Sci* **94**, 3288–3294.
123. Fuentes MC, Lajo T, Carrión JM *et al.* (2013) Cholesterol-lowering efficacy of *Lactobacillus plantarum* CECT 7527, 7528 and 7529 in hypercholesterolaemic adults. *Br J Nutr* **109**, 1866–1872.
124. Agerholm-Larsen L, Bell ML, Grunwald GK *et al.* (2000) The effect of a probiotic milk product on plasma cholesterol: a meta-analysis of short-term intervention studies. *Eur J Clin Nutr* **54**, 856–860.
125. Hlivak P, Odraska J, Ferencik M *et al.* (2005) One-year application of probiotic strain *Enterococcus faecium* M-74 decreases serum cholesterol levels. *Bratisl Lek Listy* **106**, 67–72.
126. Rees K, Hartley L, Day C *et al.* (2013) Selenium supplementation for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* **31**, CD009671.
127. Jackson K & Lovegrove J (2013) Impact of probiotics, prebiotics and synbiotics on lipid metabolism in humans. *Nutr Aging* **1**, 181–200.
128. Pereira DI & Gibson GR (2002) Effects of consumption of probiotics and prebiotics on serum lipid levels in humans. *Crit Rev Biochem Mol Biol* **37**, 259–281.
129. Gibson GR & Roberfroid MB (1995) Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr* **125**, 1401–1412.
130. Delzenne NM, Daubioul C, Neyrinck A *et al.* (2002) Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects. *Br J Nutr* **87**, Suppl. 2, S255–S259.
131. Slavin J (2004) Whole grains and human health. *Nutr Res Rev* **17**, 99–110.
132. Brighenti F (2007) Dietary fructans and serum triacylglycerols: a meta-analysis of randomized controlled trials. *J Nutr* **137**, 11 Suppl., 2552S–2556S.
133. Brighenti F, Casiraghi MC, Canzi E *et al.* (1999) Effect of consumption of a ready-to-eat breakfast cereal containing inulin on the intestinal milieu and blood lipids in healthy male volunteers. *Eur J Clin Nutr* **53**, 726–733.
134. Luo J, Rizkalla SW, Alamowitch C *et al.* (1996) Chronic consumption of short-chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. *Am J Clin Nutr* **63**, 939–945.
135. Pedersen A, Sandström B & Van Amelsvoort JM (1997) The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. *Br J Nutr* **78**, 215–222.
136. Kruse HP, Kleessen B & Blaut M (1999) Effects of inulin on faecal bifidobacteria in human subjects. *Br J Nutr* **82**, 375–382.
137. van Dokkum W, Wezendonk B, Srikanth TS *et al.* (1999) Effect of nondigestible oligosaccharides on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. *Eur J Clin Nutr* **53**, 1–7.
138. Jackson KG, Taylor GR, Clohessy AM *et al.* (1999) The effect of the daily intake of inulin on fasting lipid, insulin and glucose concentrations in middle-aged men and women. *Br J Nutr* **82**, 23–30.
139. Causey JL, Feirtag JM, Gallager DD *et al.* (2000) Effects of dietary inulin on serum lipids, blood glucose and the gastrointestinal environment in hypercholesterolemic men. *Nutr Res* **20**, 191–201.

140. Lefxier D, Driaison F & Beylot M (2003) Addition of inulin to a moderately high-carbohydrate diet reduces hepatic lipogenesis and plasma triacylglycerol concentrations in humans. *Am J Clin Nutr* **77**, 559–564.
141. Russo F, Chimenti G, Riezzo G *et al.* (2008) Inulin-enriched pasta affects lipid profile and Lp(a) concentrations in Italian young healthy male volunteers. *Eur J Nutr* **47**, 453–459.
142. Forcheron F & Beylot M (2007) Long-term administration of inulin-type fructans has no significant lipid-lowering effect in normolipidemic humans. *Metabolism* **56**, 1093–1098.
143. Vulevic J, Drakoularakou A, Yagoob P *et al.* (2008) Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. *Am J Clin Nutr* **88**, 1438–1446.
144. Yen CH, Kuo YW, Tseng YH *et al.* (2011) Beneficial effects of fructo-oligosaccharides supplementation on fecal bifidobacteria and index of peroxidation status in constipated nursing-home residents – a placebo-controlled, diet-controlled trial. *Nutrition* **27**, 323–328.
145. Hidaka H, Hirayama M, Tokunaga T *et al.* (1990) The effects of undigestible fructooligosaccharides on intestinal microflora and various physiological functions on human health. *Adv Exp Med Biol* **270**, 105–117.
146. Davidson MH, Maki KC, Synectki C *et al.* (1998) Effects of dietary inulin on serum lipids in men and women with hypercholesterolemia. *Nutr Res* **18**, 503–517.
147. Giacco R, Clemente G, Luongo D *et al.* (2004) Effects of short-chain fructo-oligosaccharides on glucose and lipid metabolism in mild hypercholesterolemic individuals. *Clin Nutr* **23**, 331–340.
148. Yamashita K, Kawai K & Itakura M (1984) Effects of fructooligosaccharides on blood-glucose and serum-lipids in diabetic subjects. *Nutr Res* **4**, 961–966.
149. Alles MS, de Roos NM, Bakx JC *et al.* (1999) Consumption of fructooligosaccharides does not favorably affect blood glucose and serum lipid concentrations in patients with type 2 diabetes. *Am J Clin Nutr* **69**, 64–69.
150. Balcazar-Muñoz BR, Martínez-Abundis E & González-Ortiz M (2003) Effect of oral inulin administration on lipid profile and insulin sensitivity in subjects with obesity and dyslipidemia. *Rev Med Chil* **131**, 597–604.
151. Genta S, Cabrera W, Habib N *et al.* (2009) Yacon syrup: beneficial effects on obesity and insulin resistance in humans. *Clin Nutr* **28**, 182–187.
152. Vulevic J, Juric A, Tzortzis G *et al.* (2013) A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults. *J Nutr* **143**, 324–331.
153. Demigné C, Morand C, Levrat MA *et al.* (1995) Effect of propionate on fatty acid and cholesterol synthesis and on acetate metabolism in isolated rat hepatocytes. *Br J Nutr* **74**, 209–219.
154. Kok NN, Morgan LM, Williams CM *et al.* (1998) Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats. *J Nutr* **128**, 1099–1103.
155. Everard A, Belzer C, Geurts L *et al.* (2013) Cross-talk between *Akkermansia muciniphila* and intestinal epithelium controls diet-induced obesity. *Proc Natl Acad Sci USA* **110**, 9066–9071.
156. Reegan-Shaw S, Nihal M & Ahmad N (2008) Dose translation from animal to human studies revisited. *FASEB J* **22**, 659–661.
157. Ryan D, Kendall M & Robards K (2007) Bioactivity of oats as it relates to cardiovascular disease. *Nutr Res Rev* **20**, 147–162.
158. Borneo R & León AE (2012) Whole grain cereals: functional components and health benefits. *Food Funct* **3**, 110–119.
159. Tiwari U & Cummins E (2011) Meta-analysis of the effect of  $\beta$ -glucan intake on blood cholesterol and glucose levels. *Nutrition* **27**, 1008–1016.
160. Scientific Opinion on the substantiation of a health claim related to oat beta glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006. <http://www.efsa.europa.eu/de/efsajournal/pub/1885.htm>
161. Gunness P & Gidley MJ (2010) Mechanisms underlying the cholesterol-lowering properties of soluble dietary fibre polysaccharides. *Food Funct* **1**, 149–155.
162. Andersson KE, Axling U, Xu J *et al.* (2012) Diverse effects of oats on cholesterol metabolism in C57BL/6 mice correlate with expression of hepatic bile acid-producing enzymes. *Eur J Nutr* **52**, 1755–1759.
163. Hughes SA, Shewry PR, Gibson GR *et al.* (2008) *In vitro* fermentation of oat and barley derived beta-glucans by human faecal microbiota. *FEMS Microbiol Ecol* **64**, 482–493.
164. Kim HJ & White PJ (2009) *In vitro* fermentation of oat flours from typical and high beta-glucan oat lines. *J Agric Food Chem* **57**, 7529–7536.
165. Nordlund E, Aura AM, Mattila I *et al.* (2012) Formation of phenolic microbial metabolites and short-chain fatty acids from rye, wheat, and oat bran and their fractions in the metabolic *in vitro* colon model. *J Agric Food Chem* **60**, 8134–8145.
166. Connolly ML, Lovegrove JA & Tuohy KM (2010) *In vitro* evaluation of the microbiota modulation abilities of different sized whole oat grain flakes. *Anaerobe* **16**, 483–488.
167. Connolly ML, Tuohy KM & Lovegrove JA (2012) Wholegrain oat-based cereals have prebiotic potential and low glycaemic index. *Br J Nutr* **108**, 2198–2206.
168. Pischas A, Little T, Lal S *et al.* (2012) Colestyramine slows gastric emptying of liquids and reduces appetite in healthy subjects. *Neurogastroenterol Motil* **24**, 1095–1101.
169. Ooi LG, Ahmad R, Yuen KH *et al.* (2010) Lactobacillus gasserl [corrected] CHO-220 and inulin reduced plasma total cholesterol and low-density lipoprotein cholesterol via alteration of lipid transporters. *J Dairy Sci* **93**, 5048–5058.
170. Tanaka H, Doesburg K, Iwasaki T *et al.* (1999) Screening of lactic acid bacteria for bile salt hydrolase activity. *J Dairy Sci* **82**, 2530–2535.
171. Kim GB, Yi SH & Lee BH (2004) Purification and characterization of three different types of bile salt hydrolases from *Bifidobacterium* strains. *J Dairy Sci* **87**, 258–266.